Wells Fargo Maintains Equal-Weight on Amgen, Raises Price Target to $435
Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $400 to $435.
Stocks · News reference
Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'
China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s growing influence in medicine.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Want $500 a Month in Passive Income? Start With This Brilliant Dividend ETF.
The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as an effective vehicle for generating sustainable passive income through dividends. With a 3.2% yield and a history of increasing annual dividends since 2011, investors would need approximately $187,500 invested to generate $500 monthly in dividend income. The fund focuses on high-quality dividend-paying stocks and has delivered 13.4% annual returns since inception.
If the AI Boom Slows Down, History Says This Is the Smartest Way to Protect Your Long-Term Portfolio
As concerns grow about a potential AI market slowdown due to inflation, rate hikes, and geopolitical tensions, investors should consider diversifying into dividend-focused ETFs like SCHD. The Schwab U.S. Dividend Equity ETF offers exposure to 100 stable, dividend-paying stocks across multiple sectors, providing a defensive hedge against AI stock volatility while delivering steady income and historical returns of 243% over the past decade.
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ
Fidelity's FHLC and Invesco's IBBQ offer different healthcare investment strategies. FHLC provides broad exposure to 365 healthcare holdings with a lower 0.08% expense ratio and 1.2% dividend yield, while IBBQ focuses on biotech with higher volatility, delivering 56.4% 1-year returns but experiencing a 37.9% maximum drawdown. The choice depends on investor risk tolerance and diversification preferences.
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?
Bristol Myers Squibb's Camzyos demonstrated durable reductions in LVOT obstruction over five years with 97.4% of patients achieving target gradients. Sales surged 74% year-over-year to $729 million in H1 2026. The company seeks FDA approval for adolescents with a decision expected by September 30, 2026. However, competition is intensifying with Cytokinetics' Myqorzo approved in December 2025 and Edgewise Therapeutics advancing EDG-7500 in clinical trials.
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths
Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.